These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38358081)

  • 1. Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies.
    Leon-Astudillo C; Brooks O; Salabarria SM; Coker M; Corti M; Lammers J; Plowman EK; Byrne BJ; Smith BK
    Pediatr Pulmonol; 2024 May; 59(5):1364-1371. PubMed ID: 38358081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trajectory of change in the swallowing status in spinal muscular atrophy type I.
    Choi YA; Suh DI; Chae JH; Shin HI
    Int J Pediatr Otorhinolaryngol; 2020 Mar; 130():109818. PubMed ID: 31945686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible endoscopic evaluation of swallowing in children with type 1 spinal muscular atrophy.
    Zang J; Johannsen J; Denecke J; Weiss D; Koseki JC; Nießen A; Müller F; Nienstedt JC; Flügel T; Pflug C
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1329-1338. PubMed ID: 36209319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Swallowing Problems in Spinal Muscular Atrophy Types 2 and 3: A Clinical, Videofluoroscopic and Ultrasound Study.
    van der Heul AMB; Nievelstein RAJ; van Eijk RPA; Asselman F; Erasmus CE; Cuppen I; Bittermann AJN; Gerrits E; van der Pol WL; van den Engel-Hoek L
    J Neuromuscul Dis; 2023; 10(3):427-438. PubMed ID: 37005890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of feeding difficulties using videofluoroscopic swallow study and swallowing therapy in infants and children.
    Chou Y; Wang LW; Lin CJ; Wang LY; Tsai WH; Ko MJ
    Pediatr Neonatol; 2023 Sep; 64(5):547-553. PubMed ID: 36849324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD).
    Waito AA; Steele CM; Peladeau-Pigeon M; Genge A; Argov Z
    Dysphagia; 2018 Dec; 33(6):789-802. PubMed ID: 29725764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment.
    McGrattan KE; Shell RD; Hurst-Davis R; Young SD; O'Brien E; Lavrov A; Wallach S; LaMarca N; Reyna SP; Darras BT
    J Neuromuscul Dis; 2023; 10(4):531-540. PubMed ID: 37092232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study.
    van der Heul AMB; Cuppen I; Wadman RI; Asselman F; Schoenmakers MAGC; van de Woude DR; Gerrits E; van der Pol WL; van den Engel-Hoek L
    J Neuromuscul Dis; 2020; 7(3):323-330. PubMed ID: 32333596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec.
    Leon-Astudillo C; Wagner M; Salabarria SM; Lammers J; Berthy J; Zingariello CD; Byrne BJ; Smith BK
    Sleep Med; 2023 Jan; 101():234-237. PubMed ID: 36442421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
    Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
    J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
    Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
    JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
    Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
    J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
    Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
    J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DySMA - an Instrument to Monitor Swallowing Function in Children with Spinal Muscular Atrophy ages 0 to 24 Months: Development, Consensus, and Pilot Testing.
    Zang J; Witt S; Johannsen J; Weiss D; Denecke J; Dumitrascu C; Nießen A; Quitmann JH; Pflug C; Flügel T
    J Neuromuscul Dis; 2024; 11(2):473-483. PubMed ID: 38457144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysphagia Phenotypes in Spinal Muscular Atrophy: The Past, Present, and Promise for the Future.
    McGrattan KE; Graham RJ; DiDonato CJ; Darras BT
    Am J Speech Lang Pathol; 2021 May; 30(3):1008-1022. PubMed ID: 33822657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Evaluation of Swallowing with Videofluoroscopy in Patients with Locally Advanced Head and Neck Cancer After Chemoradiation.
    Xinou E; Chryssogonidis I; Kalogera-Fountzila A; Panagiotopoulou-Mpoukla D; Printza A
    Dysphagia; 2018 Oct; 33(5):691-706. PubMed ID: 29572573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.
    Hjartarson HT; Nathorst-Böös K; Sejersen T
    Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.